---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065234"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:52:53.649651+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics stockholders approve reverse stock split at ratio from 1:2 to 1:30

## Summary
- Stockholders approved reverse stock split at ratio between 1:2 and 1:30, board to set exact ratio and timing.
- Proposal passed with 55,438,144 votes for, 1,521,271 against, 33,539 abstaining, no broker non-votes.
- Adjournment proposal also approved with 55,461,067 for, 1,491,733 against, 40,154 abstaining.
- Special meeting held on February 23, 2026; both proposals received overwhelming stockholder support.

## SEC filing metadata
- accession: 0001193125-26-065234
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/0001193125-26-065234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/xlo-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065234
- JSON: https://secwatch.observer/filing/0001193125-26-065234.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.